Abstract

BackgroundSince the discovery of cell-free DNA (cfDNA) in maternal plasma, it has opened up new approaches for non-invasive prenatal testing. With the development of whole-genome sequencing, small subchromosomal deletions and duplications could be found by NIPT. This study is to review the efficacy of NIPT as a screening test for aneuploidies and CNVs in 42,910 single pregnancies.MethodsA total of 42,910 single pregnancies with different clinical features were recruited. The cell-free fetal DNA was directly sequenced. Each of the chromosome aneuploidies and the subchromosomal microdeletions/microduplications of PPV were analyzed.ResultsA total of 534 pregnancies (1.24%) were abnormal results detected by NIPT, and 403 pregnancies had underwent prenatal diagnosis. The positive predictive value (PPV) for trisomy 21(T21), trisomy 18 (T18), trisomy 13 (T13), sex chromosome aneuploidies (SCAs), and other chromosome aneuploidy was 79.23%, 54.84%, 13.79%, 33.04%, and 9.38% respectively. The PPV for CNVs was 28.99%. The PPV for CNVs ≤ 5 Mb is 20.83%, for within 5–10 Mb 50.00%, for > 10 Mb 27.27% respectively. PPVs of NIPT according to pregnancies characteristics are also different.ConclusionOur data have potential significance in demonstrating the usefulness of NIPT profiling not only for common whole chromosome aneuploidies but also for CNVs. However, this newest method is still in its infancy for CNVs. There is still a need for clinical validation studies with accurate detection rates and false positive rates in clinical practice.

Highlights

  • A total of 534 pregnancies (1.24%) were abnormal results detected by non-invasive prenatal testing (NIPT), and 403 pregnancies had underwent prenatal diagnosis

  • positive predictive value (PPV) of NIPT according to pregnancies characteristics are different

  • The Creative Commons Public Domain Dedication waiver applies to the data made available in this article, unless otherwise stated

Read more

Summary

Introduction

Since the discovery of cell-free fetal DNA (cffDNA) in maternal plasma in 1997 [1], it has opened up new approaches for non-invasive prenatal testing (NIPT). 2011, massively parallel sequencing (MPS) for fetal aneuploidies has become available in more than 60 countries. NIPT using cfDNA circulating in maternal blood has opened the door to early, accurate, and safe prenatal testing, and it has been available clinically for over 8 years [2]. A growing number of studies demonstrate that NIPT could reduce the incidence of unnecessary invasive procedures and iatrogenic fetal loss [4]. Since the discovery of cell-free DNA (cfDNA) in maternal plasma, it has opened up new approaches for non-invasive prenatal testing. This study is to review the efficacy of NIPT as a screening test for aneuploidies and CNVs in 42,910 single pregnancies

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call